Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $35.50 Consensus PT from Analysts
Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) have received a consensus rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have covered the stock in the last […]
Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) have received a consensus rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have covered the stock in the last […]
